Core Insights - Bio-Techne Corporation has expanded its partnership with Leica Biosystems to enhance spatial biology research through automation of the RNAscope™ Multiomic LS Assay and protease-free workflows [1][3] Company Overview - Bio-Techne is a global life sciences company that generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [5] - Leica Biosystems is a leader in cancer diagnostics and workflow solutions, operating in over 100 countries and dedicated to advancing cancer diagnostics [6] Product Innovations - The RNAscope™ Multiomic LS Assay allows for the simultaneous fluorescent detection of up to six RNA and/or protein biomarkers on a single slide, preserving sample integrity [2] - ACD has introduced a protease-free workflow for RNAscope™ 2.5 single-plex assays on the Leica BOND RX staining instrument, enhancing multiomic visualization capabilities [2] Strategic Importance - The automation of RNAscope™ assays on the Leica BOND RX platform is seen as a significant milestone in spatial multiomics research, providing a fully automated solution that preserves sample integrity [3] - The partnership has been in place since 2015 and aims to streamline in-situ hybridization workflows, contributing to over 12,000 peer-reviewed publications [3]